Cargando…
Immunotherapy for hepatocellular carcinoma: current status and future perspectives
The discovery of the immune checkpoint mechanism has contributed greatly to recent advances in cancer treatment. The anticytotoxic T lymphocyte-associated protein 4 antibody ipilimumab was first approved as a therapeutic drug for malignant melanoma in the USA in 2011; since then, antiprogrammed cell...
Autores principales: | Okusaka, Takuji, Ikeda, Masafumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307608/ https://www.ncbi.nlm.nih.gov/pubmed/30622744 http://dx.doi.org/10.1136/esmoopen-2018-000455 |
Ejemplares similares
-
Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives
por: Hijioka, Susumu, et al.
Publicado: (2021) -
Immunotherapy for hepatocellular carcinoma: Current status and future perspectives
por: Mandlik, Deepa S, et al.
Publicado: (2023) -
Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future
por: Ikeda, Masafumi, et al.
Publicado: (2015) -
Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives
por: Pan, Yasi, et al.
Publicado: (2020) -
Current status and future perspectives of radiomics in hepatocellular carcinoma
por: Miranda, Joao, et al.
Publicado: (2023)